Clinical trials
Phase 1/2 Hematologic Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
39 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Terminated | 7 |
| Recruiting | 4 |
| Unknown status | 4 |
| Active, not recruiting | 3 |
| Not yet recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| BioMarin Pharmaceutical | 3 |
| Hellenic Society of Hematology | 3 |
| Seagen Inc. | 2 |
| Spark Therapeutics, Inc. | 2 |
| AO GENERIUM | 1 |
| Ariad Pharmaceuticals | 1 |
| Astex Pharmaceuticals, Inc. | 1 |
| Atavistik Bio, Inc | 1 |
| Baylor College of Medicine | 1 |
| Celgene | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hematologic Diseases | 39 |
| Neoplasms | 12 |
| Hemorrhagic Disorders | 10 |
| Genetic Diseases, Inborn | 9 |
| Multiple Myeloma | 9 |
| Blood Protein Disorders | 8 |
| Neoplasms, Plasma Cell | 8 |
| Blood Coagulation Disorders | 7 |
| Leukemia | 7 |
| Paraproteinemias | 7 |
Trials
Showing 1 to 25 of 39. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.